Unknown

Dataset Information

0

IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10.


ABSTRACT: The objective of this study was to test the capacity of a newly developed fusion protein of interleukin 4 (IL-4) and IL-10 [IL4-10 fusion protein (FP)] to shift multiple pro-inflammatory pathways towards immune regulation, and to inhibit pro-inflammatory activity in arthritis models. The effects of IL4-10 FP in comparison with IL-4, IL-10 and IL-4 plus IL-10 on pro- and anti-inflammatory mediators, T cells and immunoglobulin (Ig) receptors in favour of immunoregulatory activity were studied. In addition, the capacity of IL4-10 FP to inhibit pro-inflammatory activity in ex-vivo and in-vivo arthritis models was investigated. IL4-10 FP robustly inhibited pro-inflammatory cytokine [IL-1?, tumour necrosis factor (TNF)-?, IL-6 and IL-8] production in whole blood cultures, mediated by both the IL-10 and the IL-4 moiety. IL4-10 fusion protein induced IL-1 receptor antagonist (IL-1RA) production and preserved soluble TNF receptor (sTNFR) levels, strongly increasing IL-1RA/IL-1? and sTNFR/TNF-? ratios. In addition, IL4-10 FP strongly inhibited T helper (Th) type 1 and 17 cytokine secretion, while maintaining FoxP3 expression and up-regulating Th2 activity. In addition, while largely leaving expression of activating Fc gamma receptor (Fc?R)I, III and Fc epsilon receptor (Fc?R) unaffected, it significantly shifted the Fc?RIIa/Fc?RIIb ratio in favour of the inhibitory Fc?RIIb. Moreover, IL4-10 FP robustly inhibited secretion of pro-inflammatory cytokines by rheumatoid arthritis synovial tissue and suppressed experimental arthritis in mice, without inducing B cell hyperactivity. IL4-10 fusion protein is a novel drug, signalling cells to induce immunoregulatory activity that overcomes limitations of IL-4 and IL-10 stand-alone therapy, and therefore has therapeutic potential for inflammatory diseases such as rheumatoid arthritis.

SUBMITTER: Steen-Louws C 

PROVIDER: S-EPMC6300648 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10.

Steen-Louws C C   Hartgring S A Y SAY   Popov-Celeketic J J   Lopes A P AP   de Smet M B M MBM   Eijkelkamp N N   Lafeber F P J G FPJG   Hack C E CE   van Roon J A G JAG  

Clinical and experimental immunology 20181111 1


The objective of this study was to test the capacity of a newly developed fusion protein of interleukin 4 (IL-4) and IL-10 [IL4-10 fusion protein (FP)] to shift multiple pro-inflammatory pathways towards immune regulation, and to inhibit pro-inflammatory activity in arthritis models. The effects of IL4-10 FP in comparison with IL-4, IL-10 and IL-4 plus IL-10 on pro- and anti-inflammatory mediators, T cells and immunoglobulin (Ig) receptors in favour of immunoregulatory activity were studied. In  ...[more]

Similar Datasets

| S-EPMC2143979 | biostudies-other
| S-EPMC6622543 | biostudies-literature
2021-02-28 | GSE150795 | GEO
2023-07-09 | GSE190111 | GEO
| S-EPMC3669341 | biostudies-literature
| S-EPMC4454631 | biostudies-other
2023-07-09 | GSE193051 | GEO
2023-07-09 | GSE193050 | GEO
2023-07-09 | GSE193054 | GEO
2023-07-09 | GSE193045 | GEO